Menu Search
Equities

Genxone SA

GX1:WSE

Genxone SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (PLN)5.36
  • Today's Change-0.06 / -1.11%
  • Shares traded121.00
  • 1 Year change-26.58%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in PLNIncome statement in PLNView more

Year on year Genxone SA's revenues fell -77.38% from 10.59m to 2.39m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a gain of 479.97k to a loss of 3.72m.
Gross margin-39.53%
Net profit margin-231.47%
Operating margin-253.56%
Return on assets-23.87%
Return on equity-24.87%
Return on investment-24.84%
More ▼

Cash flow in PLNView more

In 2023, cash reserves at Genxone SA fell by 4.17m. However, Cash Flow from Investing totalled 496.18k, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 4.62m for operations while cash used for financing totalled 45.79k.
Cash flow per share-0.4072
Price/Cash flow per share--
Book value per share4.02
Tangible book value per share2.90
More ▼

Balance sheet in PLNView more

Genxone SA appears to have little financial risk as the company holds a substantial amount of cash on its books with little or no debt.
Current ratio17.02
Quick ratio16.71
Total debt/total equity0.0028
Total debt/total capital0.0028
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.